CTNI-37. EFFICACY OF ONC201 IN PATIENTS WITH ONC201 FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA

H3 K27M-mutant diffuse midline gliomas (DMG) have a dismal prognosis. We report an integrated analysis for ONC201, a DRD2 antagonist and ClpP agonist, in patients with recurrent H3 K27M DMG administered as monotherapy in 3 clinical studies (NCT03295396, n=20; NCT02525692, n=6; or expanded access, n=...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Arrillaga-Romany, Isabel, Kurz, Sylvia, Tarapore, Rohinton S, Sumrall, Ashley, Butowski, Nicholas, Harrison, Rebecca, de Groot, John, Chi, Andrew, Shonka, Nicole, Umemura, Yoshie, Odia, Yazmin, Mehta, Minesh, Nghiemphu, Phioanh, Cloughesy, Timothy, Taylor, Lynne, Graber, Jerome, Kilburn, Lindsay, Dixit, Karan, Lu, Guangrong, Allen, Joshua, Batchelor, Tracy, Lassman, Andrew, Wen, Patrick
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Clinical Trials: Non-Immunologic
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651099/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.204
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars